Jason Lee joined Centerview Partners in 2012 and is a Partner in the San Francisco office. At Centerview, Mr. Lee has advised a broad range of life science companies across strategic advisory assignments and transactions exceeding $180 billion in value.

Mr. Lee’s recent notable healthcare transactions include advising Seagen on its sale to Pfizer for $44 billion, Immunomedics on its sale to Gilead for $21 billion, Array BioPharma on its sale to Pfizer for $11.8 billion, AveXis on its sale to Novartis for $8.7 billion, GW Pharmaceuticals on its sale to Jazz Pharmaceuticals for $7.2 billion, Mirati on its sale to Bristol Myers Squibb for up to $5.8 billion, Tesaro on its sale to GSK for $5.1 billion, Forty Seven Therapeutics on its sale to Gilead for $4.9 billion, Dicerna Pharmaceuticals on its sale to Novo Nordisk for $3.3 billion, MorphoSys on its sale to Novartis for €2.8 billion, ArQule on its sale to Merck for $2.7 billion, Ra Pharma on its sale to UCB for $2.5 billion, Synthorx on its sale to Sanofi for $2.5 billion, Dice Therapeutics on its sale to Eli Lilly for $2.4 billion, Peloton Therapeutics on its sale to Merck for up to $2.2 billion, Constellation Pharmaceuticals on its sale to MorphoSys for $1.7 billion, ARMO on its sale to Eli Lilly for $1.6 billion, Imago Biosciences on its sale to Merck for $1.3 billion, Syntimmune on its sale to Alexion for up to $1.2 billion, Eidos Therapeutics on its $1.1 billion sale of the publicly-traded minority shares to BridgeBio, Lengo Therapeutics on its sale to Blueprint for up to $465 million, Pionyr on its option transaction with Gilead.

Other notable transactions include advising Pharmacyclics on its sale to AbbVie for $21 billion, Kite Pharma on its sale to Gilead for $11.9 billion, Onyx on its sale to Amgen for $10.4 billion, InterMune on its sale to Roche for $8.9 billion, Dyax on its sale to Shire for $6.6 billion, Avanir on its sale to Otsuka for $3.5 billion, Relypsa on its sale to Galenica for $1.5 billion, Cadence on its sale to Mallinckrodt for $1.3 billion, MAP Pharmaceuticals on its sale to Allergan for $1 billion, Optimer and Trius on their sale to Cubist for $0.8 billion and $0.8 billion, respectively, Raptor on its sale to Horizon for $0.8 billion, XenoPort on its sale to Arbor for $500 million.

Mr. Lee holds an M.B.A. from Cornell University and a B.S. in Microbiology and Molecular Genetics from University of California, Los Angeles.